| 1 |
Signatures of mutational processes in human cancer
Australian Pancreatic Cancer Genome Initiative et al. · Nature
Open access |
14 Aug 2013 |
10,284 |
| 2 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie Renee Brahmer et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,632 |
| 3 |
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
Pieter van Hagen et al. · New England Journal of Medicine
Open access |
31 May 2012 |
5,583 |
| 4 |
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Joshua A Welsh et al. · Journal of Extracellular Vesicles
Open access |
Feb 2024 |
4,377 |
| 5 |
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Stephen G. O’Brien et al. · New England Journal of Medicine
Open access |
12 Mar 2003 |
3,593 |
| 6 |
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine
Open access |
17 Feb 2017 |
3,457 |
| 7 |
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner et al. · Blood
Open access |
7 Jul 2022 |
3,286 |
| 8 |
Patterns of somatic mutation in human cancer genomes
Christopher D. Greenman et al. · Nature
Open access |
Mar 2007 |
3,167 |
| 9 |
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker et al. · JAMA
Open access |
20 Jun 2017 |
2,963 |
| 10 |
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al. · European Urology
Open access |
7 Nov 2020 |
2,876 |
| 11 |
International network of cancer genome projects
Jennifer L. Jennings et al. · Nature
Open access256 authors |
13 Apr 2010 |
2,439 |
| 12 |
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik‐Zainal et al. · Nature
Open access |
29 Apr 2016 |
2,395 |
| 13 |
Genome-wide association study identifies novel breast cancer susceptibility loci
Douglas F. Easton et al. · Nature
Open access239 authors |
27 May 2007 |
2,342 |
| 14 |
DNA Damage, Aging, and Cancer
Jan H.J. Hoeijmakers · New England Journal of Medicine
Open access |
7 Oct 2009 |
2,241 |
| 15 |
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller et al. · Nature Reviews Clinical Oncology
ReviewOpen access |
8 Dec 2020 |
2,063 |
| 16 |
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin et al. · International Journal of Gynecological Cancer
Open access |
23 Dec 2020 |
2,012 |
| 17 |
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
Mieke Kriege, Cecile T.M. Brekelmans, Carla Boetes et al. · New England Journal of Medicine
Open access |
28 Jul 2004 |
1,690 |
| 18 |
Cremophor EL
Hans A. J. Gelderblom, Jaap Verweij, Kees Nooter et al. · European Journal of Cancer
|
Sep 2001 |
1,658 |
| 19 |
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo Giovanni Casali et al. · Annals of Oncology
Open access |
28 Mar 2018 |
1,636 |
| 20 |
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou et al. · Nature
Open access362 authors |
20 Oct 2017 |
1,602 |
| 21 |
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity
Ursula Fünfschilling, Lotti M. Supplie, Don Mahad et al. · Nature
Open access |
27 Apr 2012 |
1,571 |
| 22 |
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology
|
26 Sep 2017 |
1,356 |
| 23 |
A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors
Pieter Mathijs Voorhoeve, Carlos le Sage, Mariëtte Schrier et al. · Cell
Open access |
Mar 2006 |
1,270 |
| 24 |
Lamina-Associated Domains: Links with Chromosome Architecture, Heterochromatin, and Gene Repression
Bas van Steensel, Andrew S. Belmont · Cell
Open access |
May 2017 |
1,258 |
| 25 |
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Philip A Cornford et al. · European Urology
Open access |
13 Apr 2024 |
1,253 |
| 26 |
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al. · The Lancet
Open access |
2021 |
1,226 |
| 27 |
Heating the patient: a promising approach?
Jacoba van der Zee · Annals of Oncology
Open access |
Aug 2002 |
1,224 |
| 28 |
Pan-cancer whole-genome analyses of metastatic solid tumours
Peter Priestley et al. · Nature
Open access |
23 Oct 2019 |
1,222 |
| 29 |
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Fernanda Mosele et al. · Annals of Oncology
Open access |
24 Aug 2020 |
1,221 |
| 30 |
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Nasim Mavaddat et al. · The American Journal of Human Genetics
Open access269 authors |
13 Dec 2018 |
1,213 |
| 31 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Robert Judson, Jaap Verweij, Hans A. J. Gelderblom et al. · The Lancet Oncology
Open access |
5 Mar 2014 |
1,195 |
| 32 |
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Yung Wen et al. · Neuro-Oncology
Open access |
20 Apr 2020 |
1,183 |
| 33 |
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Ruth Davies et al. · Nature Medicine
Open access |
13 Mar 2017 |
1,158 |
| 34 |
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
Remi A. Nout, VTHBM Smit, Hein Putter et al. · The Lancet
|
Mar 2010 |
1,154 |
| 35 |
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Philip A Cornford et al. · European Urology
Open access |
8 Oct 2020 |
1,142 |
| 36 |
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon et al. · Clinical Chemistry
|
28 Nov 2008 |
1,141 |
| 37 |
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller et al. · The Lancet Oncology
Open access |
5 May 2017 |
1,122 |
| 38 |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Kyriaki Michailidou et al. · Nature Genetics
Open access222 authors |
27 Mar 2013 |
1,109 |
| 39 |
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al. · Journal of Clinical Oncology
Open access |
27 Feb 2020 |
1,101 |
| 40 |
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Alessandro Gronchi et al. · Annals of Oncology
Open access |
22 Jul 2021 |
1,057 |
| 41 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al. · The Lancet Oncology
Open access |
19 Aug 2014 |
1,053 |
| 42 |
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Guido Rindi, Özgür Mete, Silvia Uccella et al. · Endocrine Pathology
Open access |
Mar 2022 |
1,029 |
| 43 |
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf et al. · New England Journal of Medicine
Open access |
2 Sep 2020 |
1,029 |
| 44 |
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al. · New England Journal of Medicine
Open access |
15 Nov 2017 |
1,008 |
| 45 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al. · The Lancet
Open access |
3 Jun 2019 |
973 |
| 46 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al. · Blood
Open access |
22 Mar 2016 |
945 |
| 47 |
Summary of the Recommendations on Sexual Dysfunctions in Men
Francesco Montorsi et al. · The Journal of Sexual Medicine
|
29 Oct 2010 |
944 |
| 48 |
Testicular germ-cell tumours in a broader perspective
J. Wolter Oosterhuis, Leendert H. J. Looijenga · Nature reviews. Cancer
Review |
Mar 2005 |
932 |
| 49 |
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Philippe Moreau, Jesús F. San Miguel, Pieter Sonneveld et al. · Annals of Oncology
Open access |
6 Apr 2017 |
882 |
| 50 |
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza et al. · New England Journal of Medicine
Open access |
27 Mar 2023 |
865 |